Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

Matthew D. Hellmann, MD
Published: Wednesday, Jul 12, 2017



Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.

The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
 
SELECTED
LANGUAGE


Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.

The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x